Purpose of Review The field of extracellular vesicles is growing exponentially because of the important role that these extracellular organelles had on cell to cell communication, triggering a large number of review compilations focusing on different aspects of their biology. Although their importance as effectors or potential biomarkers is well covered, the highlight of extracellular vesicles as carriers of active enzymes which have the capability to transform the surrounding media is less covered by bibliographic studies. In the present review, we focus our attention on enzymatic activity carried by vesicles, with special attention on their contribution to liver conditions. Recent Findings Extracellular vesicles are circulating membrane-bound entities, characterized by a specific cargo. This cargo depends on the parental cell and the stimulus that triggers their release. Interestingly, the cargo includes active enzymes which had the ability of transforming the extracellular environment. Among them, extracellular vesicles derived from hepatocytes harbor specific liver enzymes that may cause an impact in the surrounds and target cells. Summary In this review, we summarize different active enzymes described in extracellular vesicles and we focus on enzymatic activities associated to liver damage. Since their release increases under liver damage conditions, their activity impact could play a role in the pathogenesis of liver and liver-associated diseases. Numerous examples in different liver conditions provided evidence of the potential of extracellular vesicles as therapeutic targets.
Introduction
Extracellular vesicles (EVs) are heterogeneous membraneenclosed vesicles released by cells [1] . There are three main types of EVs based on their size and mechanism of formation: exosomes, microvesicles (MVs), and apoptotic bodies (see Fig. 1 ). Exosomes are the smallest EVs (30-150 nm) [2] , and their formation occurs in the multivesicular bodies (MVBs) of the endocytic and secretory pathway [3, 4] . Another mechanism permits the formation of MVs, which are formed directly by the outward budding of the plasma membrane (50-5000 nm) [5] . Finally, apoptotic bodies are EVs (1-5 μm) originated from cells undergoing apoptosis [6] .
First observations of circulating vesicles were reported in 1946 by Chargaff and West [7] . They observed pro-coagulant platelet-derived particles in normal plasma. Later on, in 1968, Clarke Anderson identified matrix vesicles associated with the calcification process [8] . Subsequent studies determine that transferrin receptors were released to the extracellular media by reticulocytes using vesicles [9] [10] [11] [12] , and first insights into the subcellular origin of the released vesicles were described soon afterwards; the term exosomes was designed for 40-100-nm vesicles released during reticulocyte differentiation as a consequence of MVBs' fusion with the plasma membrane [13, 14] . One decade later, exosomes were found to be released by B lymphocytes and dendritic cells through a similar route [15, 16] . Later, the reported evidence that vesicles contain RNA, and that vesicular RNA could be translated by acceptor cells [9, 10] , initiate an exponential growth in the field since vesicles become a major tool in cell-to-cell communication. However, this also brought confusion to the field with respect to the nomenclature and types of vesicles analyzed. Different reviews had shaped the accepted division in terms of vesicle population [17] and standards for quality publication in the fields have been described [18] .
EVs are secreted from donor to recipient cells allowing intracellular communication, either in a paracrine or endocrine manner [19, 20] . One of the examples of the latest was given by tumor cells that favor the formation of a pre-metastatic niche by releasing EVs [21] . This effect, as well as other processes influenced by EVs, is mediated by a complex message encoded by the proteins, different nucleic acid biotypes, lipids, and metabolites that they contain. The cargo would be transferred from donor cells to recipient cells, inducing changes in gene or protein expressions that finally would impact in its proliferation, differentiation, or metabolism [22, 23] . Moreover, the role of vesicles has been highlighted in physiological processes, such as immune function or pregnancy, but also in pathological conditions such as metabolic and neurodegenerative diseases and cancer [24] . Remarkably, because vesicles are circulating, modification of the EV's cargoes can be used as a source for potential non-invasive biomarkers of different diseases [22] , and recently their role in the so-called liquid biopsy has been reinforced [25] .
The very same characteristic of being circulating and target distant cells has been seen as an opportunity for therapeutic applications. Studies using stem cell-derived EVs have demonstrated that exosomes, per se, are a novel therapeutic target for diseases [26, 27] . Thus, MSC-derived EVs have been identified as an important therapeutic target for liver disease, to protect against acute tubular injury, and to reduce myocardial ischemia/perfusion damage [26, 28, 29] .
The liver is a complex organ with different types of cells, and the characterization of the vesicles released by each of the sources was reviewed elsewhere [30] . Among them, hepatocytes released EVs loaded with a cargo characterized by the presence of proteins and transcripts specific of the hepatocyte function [31] . They play a role in cell communication [4] as well as in liver regeneration [32] . It has been described that there is an increase of circulating vesicles from liver origin after acute liver damage [33] and also in chronic liver conditions [34] . In addition, studies in relation to pathogenesis of different liver diseases have demonstrated implication of aberrant biogenesis of EVs [28] .
In the present review, we focus on the importance of the enzymatic activity of EVs and more extensively in enzymatic activity associated to EVs in liver diseases. The fact that circulating EVs carry activities usually confined to the liver opens a new landscape in the development and pathogenesis of liver-associated diseases. 
Enzymatic Activity of Extracellular Vesicles
The very first descriptions of exosomes derived from reticulocytes report enzymatic activity associated to the membrane. Those activities included acetylcholinesterase, cytochalasin B binding (glucose transporter), nucleoside binding (i.e., nucleoside transporter), Na + -independent amino acid transport, and the transferrin receptor [35] . Specifically, the activity of acetyl-cholinesterase was adopted to quantify the presence of reticulocyte exosomes in different kinds of assays [36, 37] or to discriminate between HIV particles and exosomes [38] .
However, not all vesicles harbor the same enzymatic activities, and earlier it was discovered that lysosome activities found in the exosome pellet were excluded from transferrin receptor-containing exosomes, suggesting that there is a specific mechanism to segregate and externalize specific plasma membrane proteins [39] . Moreover, since different kinds of mechanisms are involved in the generation of vesicles [17] , a wide variety of enzymes have been associated to EVs [6, 40] . One of the roles that secretion of EVs may play is to get rid of inactive or excessive enzymes, such COX2. This enzyme is secreted via exosomes through the endoplasmic reticulum-Golgi pathway, when an excess of the enzyme is generated [41] . The excretion of protein COX2 is significantly enhanced by prolonged exposure to arachidonic acid, the substrate of the protein, and the authors suggested that exosome secretion of arachidonic acid-activated COX2 constitutes a way of getting rid of damaged proteins [42] .
Other activities reported in EVs are the ATPase and GTPase activities of HSP60, detected in amniotic fluid [37] . Further studies have also shown that HSP60 is actively secreted by human tumor cells [43] .
The fact that functional enzymes are packaged in EVs opens a door for different functionality and diagnostic opportunities. Epithelial cells package the lysyl oxidase-like 2 (LOLX2) protein under hypoxic conditions, an enzyme with an important activity in remodeling epithelial cell matrix, suggesting that EVs play also a direct role, not mediated by acceptor cells, in fibrosis and wound healing [44] . This report reaffirms the importance of EVs in extracellular matrix remodeling, firstly suggested by the description of EVs harboring active metalloproteinases that can interact with the extracellular matrix [45] . They can alter significantly the metabolome of extracellular environment and the availability of nutrients for cells, for instance harboring an active asparaginase [46] . Furthermore, vesicles released by osteoclast play an important role in the mineralization of the bone through active phospholipase activity [47] .
Regarding diagnostic purposes, it has been described that urinary EVs isolated from animals with induced renal damage show increased levels of glutamyl aminopeptidase (GluAp) activity in urinary EVs. In the experimental conditions, this activity was used as an early predictive biomarker of renal dysfunction in cisplatin-induced nephrotoxicity, and the measurement in EV fractions was able to detect proximal tubular damage independently of glomerular filtration status [48] . Indeed, prostate cancer cells also secrete an increased amount of prostate-specific membrane antigen (PSMA) in exosomes. Although PSMA associated to vesicles exhibits a higher amount of glycosylation and partial proteolysis, it retains functional carboxypeptidase activity. This suggested a possible role of PSMA in prostate cancer progression and provides opportunities for developing non-invasive approaches for diagnosis or prognosis of prostate cancer [49] . In addition, it has been observed that diverse cancer cell types produce exosomes which harbor CD39 and CD73 active enzymes that participate in the production of adenosine. Interestingly, blockade of CD73 activity in the vesicles showed strong inhibition of the ability of the EVs to hydrolyze AMP, suggesting that CD73 accounts for approximately 75% of this enzymatic activity. The inhibition of CD39 also showed a reduction of the activity. The 5′AMP converted to adenosine by EVs inhibits T-cell activation independently of T-cell CD73 expression. Therefore, EV enzymatic activity in the production of extracellular adenosine plays an important role in negative modulation of T cells in the tumor environment and provides a target for a new therapeutic approach [50] . Interestingly, also anti-inflammatory effect has been attributed to the release of active purine nucleoside phosphorylase associated to EVs released by microglia as a response to extracellular ATP. ATP accumulates in extracellular matrix during inflammatory events in the brain, and the secretion of active purine nucleoside phosphorylase would counteract the presence of purine signaling [20] .
Together, all these are examples of the retained functionality of enzymes packaged in EVs acting both physiologically and under pathological conditions (Fig. 2) , which likely has a relevant impact on their environment.
Enzymes in EVs of Liver Origin
The liver is a vital organ with a specific set of functions that regulate carbohydrate, protein, amino acid, and lipid metabolisms, and is also involved in detoxification processes and blood homeostasis. Hepatocytes are highly specialized and differentiated cells that contain a subset of proteins specific for carrying out their functions. First description of EVs from liver origin already pointed that EVs released by primary cultures of rat hepatocytes included several of those specific proteins. In fact, liver damage had a dramatic effect in the proteomic composition of secreted EVs [31, 33] . Previously, it had been reviewed in a systematic way the presence of enzymes in EVs with function in the metabolism of xenobiotics [51] . The current section is focused primarily in those enzymes whose activity is detected as associated to liver pathologies (see Table 1 and Fig. 3 ).
Arginase 1
Arginase 1 (Arg1) is an enzyme responsible of cleaving arginine to form urea and L-ornithine, the last step in the urea cycle [60] . This is a critical regulatory step in the synthesis of nitric oxide and the vascular function. With the synthesis of urea, mammals get the protection against excess ammonia, whereas ornithine participates in cell proliferation, collagen formation, and other physiological functions. High levels of arginase activity have been linked to dysfunction and pathologies of the respiratory and cardiovascular systems, kidney, and central nervous system [61] .
Our group performed the first identification of Arg1 loaded in EVs derived from primary cultures of rat hepatocytes by proteomics [31] and described an increase in their release under hepatocyte toxicity [33] . Moreover, by untargeted UPLC-MS/MS, the enzyme was probed to be active inducing a depletion of arginine in serum [52] and potentially altering the relaxation capabilities of the endothelium [53] . Arginase activity has been used as an indicator of liver damage [62] , and using animal models of drug-induced liver damage, arginase activity in blood correlated with transaminases [53] . The fact that the arginase protein has been observed as associated to circulating vesicles, probably recruited by Flot1 [63] , opens new possibilities to target this enzyme to treat pulmonary hypertension associated to liver damage, considering that circulating EVs from hepatic origin can be trapped in the lung [64] .
Argininosuccinate Synthase (ASS1)
ASS1 protein is an enzyme that participates in the urea cycle, catalyzing the conversion of citrulline and aspartate to argininosuccinate. Due to changes in the amino acid metabolism, downregulation of ASS1 enzyme has been associated with the increase of metastasis and poor prognosis in different types of cancer [65, 66] . In addition, mutations in the ASS1 gene can [59] cause type I citrullinemia, a liver disease that stops the processing of excess nitrogen into urea [67, 68] . Recently, a first step for EV therapy has been attempted using EVs purified from human hepatic stem cells with an intact ASS1 gene. The EVs carried functional ASS1 protein and were able to restore the ASS1 function, and therefore, the urea production, when given to hepatic stem cells from a citrullinemia patient, with mutated ASS1 gene. This result proposes that acceptor cells can make use of the enzymes transported in the EVs [54] and supports the use of EVs as therapeutic agents.
Catechol O-Methyltransferase (COMT)
COMT protein is an enzyme that degraded catecholamines catalyzing the transfer of a methyl group from S-adenosylmethionine to catecholamines as dopamine, epinephrine, and norepinephrine. There are two isoforms for COMT, soluble (S-COMT) and membrane-bound (MB-COMT) isoforms [69, 70] . The activity of COMT has been implicated in different liver processes, such as glucose homeostasis and establishment and progression of obesity and diabetes [71, 72] . In addition, COMT has been linked to cancer, pain, and eating, neuropsychiatric, and cardiovascular disorders [73] [74] [75] [76] [77] .
The presence of this enzyme was detected for the first time in EV preparations isolated from hepatocytes by proteomics analysis [31] . In a posterior study, it has been demonstrated that the enzyme carried in rat hepatocyte-derived EVs is also active [78] . In addition, it has been reported that there is an increase in the amount of circulating EV carrying COMT after induced liver injury [33] . Confirming this result, COMT was identified as part of a fingerprint of hepatotoxicity [79] . Since EVs from hepatic origin had a wide bio-distribution, which includes the central nervous system [64] , the potential effect of active COMT exported in such way should be further explored.
Carboxylesterase 3 (CES3)
CES3 protein is an enzyme involved in the hydrolysis and transesterification of different xenobiotics, such as cocaine and heroin. In addition, it is involved in the metabolism of different drugs containing ester, carbamate, thioester, and amide groups [80] . It is predominantly located in endoplasmic reticulum of hepatocytes and adipocytes [81, 82] . Dysregulation of this enzyme has been linked to different liver diseases, for instance, obesity, diabetes, and steatohepatitis [83, 84] . Upon liver damage, there is also an increase of CES activity in the blood [85] , and consequently, CES3 has been also suggested as responsible for cardiovascular symptoms and atherosclerosis derived from liver damage [86] . Recently, it has been observed that the release of CES3 after liver damage is associated to EVs, and the increase of circulating EVs loaded with CES3 after drug-induce liver injury (DILI) [33] points toward the participation of those vesicles in the pathogenesis of described extrahepatic symptoms. Taken together, those studies indicate that CES3 could Fig. 3 Circulating EVs released from liver. They spread enzymatic activity to different tissues constituting metabolic nano-machines that may modify metabolism of distant tissues. They have been also started to be employed as vehicle for enzymes with therapeutic purposes be used both as a biomarker and a therapeutic target for different liver conditions.
Cytochromes P450 (CYPs)
CYPs proteins form a superfamily of enzymes that play a central role in drug and xenobiotic metabolism. It is also involved in steroid hormone synthesis and the conversion of polyunsaturated fatty acids to biologically active molecules among other functions [87] . This family of enzymes are monooxygenases that catalyze phase I detoxification reactions [88] . Among them, CYP2E1 is localized in the mitochondria of hepatocytes, and interestingly, despite constituting less than 2% of all hepatic cytochromes, it is responsible for the metabolization of approximately 25% of clinically used drugs [89] . As a byproduct, the CYP2E1 activity induces ROS and reactive metabolites associated to the increase in oxidative stress and cellular toxicity [90] .
The presence of cytochromes in rat hepatocytederived EVs was described in vitro [31] , but also in vivo, where increasing values of active Cyp2d1 was observed in rats under DILI challenge [55] , and interestingly, it has been described that there is an increasing activity of CYP2E1 in circulating EVs isolated from human samples after alcohol exposure [56] . Potentially, circulating active cytochromes could trigger activation of drugs, such as acetaminophen, which could end up in tissue damage, in the same way that liver-produced toxic metabolites are toxic for other tissues [91] .
Manganese Superoxide Dismutase (MnSOD)
MnSOD protein is an antioxidant enzyme that participates in the mitochondrial respiration by detoxifying the free radical superoxides [92] . In relation with the critical role of MnSOD in the defense against reactive oxygen species, it has been implicated in different diseases, such as type 2 diabetes, cardiovascular diseases, and cancer [93] [94] [95] . For instance, MnSOD overexpression originated a reduction of EV-associated PYGB protein, being EVs containing PYGB, a sensitive biomarker of cardiac injury [96] .
Yao and collaborators reported the potential use of MSC-EVs as a therapeutic resource to treat ischemiareperfusion injury (IRI). IRI is a severe injury caused by the interruption of blood flow to the liver and is characterized by inflammation and oxidative stress after ATP depletion [97] . In their study, the authors found that the enzyme MnSOD, which was encapsulated in human umbilical cord-derived mesenchymal stem cell EVS (huc-MSC-EVs), reduced oxidative stress in the hepatic IRI model [57] . This result again confirms that EVs could work as a therapeutic vehicle, giving capabilities to the acceptor cells that can be used in therapeutics.
Sphingosine-1-Phosphate Kinase and Neutral Sphingomyelinase 1
The sphingolipid biosynthetic pathway is a tight regulated pathway that has a major role in cell signaling and proliferation [98, 99] . Alterations on the regulation of this pathway have been described in non-alcoholic steatohepatitis (NASH) and cancer [100, 101] . Through EVs, active enzymes break into cells and modify the equilibrium between the metabolites involved in the sphingolipid pathway and had an impact on cell proliferation. Two different examples are described in the literature, with implications for therapeutics. On one hand, Sphingomyelinase 1 (SMase1) is an enzyme that catalyzes the hydrolysis of sphingomyelin to ceramide and phosphocholine [102] . It has been described that SMase1 is downregulated on glia tumors [103] . This enzyme is active in EVs and, when captured by tumor cells, it is responsible for the reduction of cancer cell proliferation and the increase of apoptosis in hepatocarcinoma [58] . The enzyme activity causes a reduction of the ceramide/sphingosine ratio, but also it is related to the activation of apoptosis [104] , so the provided active enzymes to the cells become the switch that redirects hepatocarcinoma cells toward death. On the other hand, EVs loaded with ceramidase and sphingosine kinases trigger liver regeneration, by generating Sphingosine-1-phosphate (S1P). By transferring the synthetic machinery to produce S1P, EVs released by intact hepatocytes that fuse with liver cells after traumatic injuries such as hepatectomy and ischemia/ reperfusion injury facilitate liver regeneration [59] . Interestingly, while extracellular S1P results in cell death both in vitro and on liver regeneration in vivo [105, 106] , intracellular S1P has been shown to promote cell proliferation in a variety of cell types [107] . Hepatocytes can transfer the substrate (ceramide) and the enzymes to restore homeostasis after liver injury, and ameliorate liver condition after damage.
Both studies probe the possibility of use EVs to deliver enzymes that restore the cell homeostasis, favoring regeneration after liver damage or stopping cell proliferation of tumor cells. Taking advantage of EVs as enzyme transportation vehicle, new therapy opportunities are open for liver diseases.
Conclusions
This review emphasizes the enzymatic activities that are present in cell-secreted EVs that present vesicles as truly circulating metabolic nano-machines able in a coordinated manner to carry specific activities in tissues that are distant from the tissues of origin. Although the impact of those activities in the body homeostasis is still unknown, what is known is that the acceptor cells will make use of the toolkit handled in the EVs' cargo [53, 57] . With respect to liver diseases, this phenomenon could be of great importance, given the degree of specialization that this organ has in blood homeostasis, detoxification, and xenobiotic metabolism. The impact that those enzymes would have in extrahepatic tissues could be variable, but first studies point toward their involvement in pathology [53] . As a consequence, a wide range of therapeutic opportunities appear either aiming extrahepatic activities as therapeutic targets or reinforcing those activities in engineered EVs harbor adequate set of enzymes, as it has been done for anti-inflammatory activities [108] .
